, , p.2012, 2013.
, Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis & Rheumatism, vol.65, pp.1-11
Epidemiology of giant cell arteritis and polymyalgia rheumatica, Arthritis & Rheumatism, issue.10, pp.1454-1461, 2009. ,
Polymyalgia rheumatica and giant cell arteritis a systematic review, JAMA -Journal of the American Medical Association, vol.315, issue.22, pp.2442-2458, 2016. ,
,
, The American College of Rheumatology 1990 Criteria for the classification of vasculitis Introduction, Arthritis & Rheumatism, vol.33, issue.8, pp.1065-1067
Does This Patient Have Temporal Arteritis?, JAMA, vol.287, issue.1, 2002. ,
Contemporary Prevalence Estimates for Giant Cell Arteritis and Polymyalgia Rheumatica, Seminars in Arthritis and Rheumatism, vol.47, issue.2, pp.253-256, 2015. ,
,
, , 2016.
, Risk factors for permanent visual loss in biopsy-proven giant cell arteritis: A study of 339 patients, Journal of Rheumatology, vol.43, issue.7, pp.1393-1399
, Medicine, vol.111, issue.3, pp.770-777
,
, Long-term remission in biopsy proven giant cell arteritis: A retrospective cohort study, Journal of Autoimmunity, vol.77, pp.39-44
Traitement de la maladie de Horton. La Revue de Médecine Interne, vol.34, pp.431-437, 2013. ,
Polymyalgia rheumatica and giant cell arteritis, N Engl J Med, vol.347, issue.4, pp.261-271, 2002. ,
De la physiopathologie de l'artérite à cellules géantes aux nouvelles cibles thérapeutiques, Revue de Medecine Interne, vol.38, issue.10, pp.670-678, 2017. ,
,
Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: A double-blind, placebo-controlled, randomized prospective clinical trial, Arthritis and Rheumatism, vol.54, issue.10, pp.3310-3318, 2006. ,
The Treatment of Giant Cell Arteritis, GEFA). Revue de Medecine Interne, vol.5, issue.3, pp.154-165, 2008. ,
,
Protocole National de Diagnostic et de Soins PNDS Artérite à Cellules Géantes (Horton), 2017. ,
Glucocorticoid therapy in giant cell arteritis: Duration and adverse outcomes, Arthritis & Rheumatism, vol.49, issue.5, pp.703-708, 2003. ,
,
, , 2016.
, Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis, Seminars in Arthritis and Rheumatism, vol.0, issue.0, pp.436-442
,
Polymyalgia rheumatica and corticosteroids: How much for how long?, Annals of the Rheumatic Diseases, vol.42, issue.4, pp.374-378, 1983. ,
,
Long-term Corticosteroid Treatment in Giant Cell Arteritis, Acta Medica Scandinavica, vol.220, issue.5, pp.465-469, 1986. ,
Prevention of glucocorticoid morbidity in giant cell arteritis, Rheumatology (United Kingdom), vol.57, pp.11-21, 2018. ,
,
Treatment of polymyalgia rheumatica and giant cell arteritis. I, 1989. ,
, Steroid regimens in the first two months, Annals of the Rheumatic Diseases, vol.48, issue.8, pp.658-661
,
Corticosteroid-related adverse events in patients with giant cell arteritis: A claims-based analysis, Seminars in Arthritis and Rheumatism, vol.46, issue.2, pp.246-252, 2016. ,
,
Prevention and management of glucocorticoid-induced side effects : A comprehensive review, Journal of American Dermatology, vol.76, issue.2, pp.201-207, 2017. ,
Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular, 2004. ,
Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis-A prospective two-year study in 273 patients, Scand J Rheumatol, vol.30, pp.260-267, 2001. ,
, , pp.2008-004896
Trial of Tocilizumab in Giant-Cell Arteritis, New England Journal of Medicine, vol.377, issue.4, pp.317-328, 2017. ,
A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis, Arthritis and Rheumatism, vol.46, issue.5, pp.1309-1318, 2002. ,
,
Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study, Ann Intern Med, vol.82, issue.5, pp.613-618, 1975. ,
, , 2009.
, EULAR recommendations for the management of large vessel vasculitis, Annals of the Rheumatic Diseases, vol.68, issue.3, pp.318-323
Relapses in Patients With Giant Cell Arteritis, Medicine, vol.93, issue.5, pp.194-201, 2014. ,
Relapses and Recurrences in Giant Cell Arteritis, Medicine, vol.90, issue.3, pp.186-193, 2011. ,
,
Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study, The Journal of Rheumatology, vol.42, issue.7, pp.1213-1217, 2015. ,
,
Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy, Medicine, vol.95, issue.19, 2016. ,
,
Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: A retrospective cohort study, Rheumatology (United Kingdom), vol.55, issue.2, pp.347-356, 2015. ,
,
A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant, 2002. ,
, Arthritis & Rheumatism, vol.47, issue.1, pp.29-35
, , 2017.
Do We Treat Patients with Large-Vessel Involvement Differently?, The American Journal of Medicine, vol.130, issue.8, pp.992-995 ,